Unique skin nodules following COVID-19 vaccination: a case report of cutaneous plasmacytosis and review of the literature.

IF 4 3区医学 Q2 VIROLOGY Virology Journal Pub Date : 2025-03-04 DOI:10.1186/s12985-025-02653-6

Xiaoxi Xu, Wuwu Ding, Haizhen Song, Dong Wang

{"title":"Unique skin nodules following COVID-19 vaccination: a case report of cutaneous plasmacytosis and review of the literature.","authors":"Xiaoxi Xu, Wuwu Ding, Haizhen Song, Dong Wang","doi":"10.1186/s12985-025-02653-6","DOIUrl":null,"url":null,"abstract":"Background: Cutaneous plasmacytosis (CP) is a rare disorder that may affect two or more organ systems, such as skin, lymph nodes or lungs. The pathogenesis of CP remains unknown, and in most cases, the condition follows a chronic and benign clinical course without spontaneous remission.Case presentation: A 50-year-old male who developed necrotizing skin nodules without other systemic abnormalities four days after the first doses of the Coronavirus disease 2019 (COVID-19) vaccination. Oral prednisone improved the lesions by approximately 70%. However, signs of CP recurrence manifested 15 days after the second dose of COVID-19 vaccination. Ultimately, the patient experienced spontaneous remission after contracting SARS-CoV-2 infection.Conclusion: This case uniquely associates COVID-19 inactivated vaccine with CP, where the same lesions appeared after two vaccinations and subsequently resolved following SARS-CoV-2 infection. This provides valuable clinical data for future studies on viral infections and cutaneous B-cell immunity.","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"22 1","pages":"57"},"PeriodicalIF":4.0000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877820/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12985-025-02653-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cutaneous plasmacytosis (CP) is a rare disorder that may affect two or more organ systems, such as skin, lymph nodes or lungs. The pathogenesis of CP remains unknown, and in most cases, the condition follows a chronic and benign clinical course without spontaneous remission.

Case presentation: A 50-year-old male who developed necrotizing skin nodules without other systemic abnormalities four days after the first doses of the Coronavirus disease 2019 (COVID-19) vaccination. Oral prednisone improved the lesions by approximately 70%. However, signs of CP recurrence manifested 15 days after the second dose of COVID-19 vaccination. Ultimately, the patient experienced spontaneous remission after contracting SARS-CoV-2 infection.

Conclusion: This case uniquely associates COVID-19 inactivated vaccine with CP, where the same lesions appeared after two vaccinations and subsequently resolved following SARS-CoV-2 infection. This provides valuable clinical data for future studies on viral infections and cutaneous B-cell immunity.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

COVID-19疫苗接种后独特的皮肤结节：皮肤浆细胞病1例报告并文献复习

背景：皮肤浆细胞病（CP）是一种罕见的疾病，可影响两个或多个器官系统，如皮肤，淋巴结或肺。CP的发病机制尚不清楚，在大多数情况下，病情遵循慢性和良性的临床过程，没有自发缓解。病例介绍：一名50岁男性，在首次接种2019冠状病毒病（COVID-19）疫苗后4天出现坏死性皮肤结节，无其他全身性异常。口服强的松使病变改善约70%。然而，在第二次接种COVID-19疫苗后15天出现CP复发迹象。最终，患者在感染SARS-CoV-2后自行缓解。结论：该病例独特地将COVID-19灭活疫苗与CP联系起来，两次接种后出现相同的病变，随后在SARS-CoV-2感染后消退。这为今后病毒感染和皮肤b细胞免疫的研究提供了有价值的临床数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Virology Journal 医学-病毒学

CiteScore

7.40

自引率

2.10%

发文量

186

审稿时长

1 months

期刊介绍： Virology Journal is an open access, peer reviewed journal that considers articles on all aspects of virology, including research on the viruses of animals, plants and microbes. The journal welcomes basic research as well as pre-clinical and clinical studies of novel diagnostic tools, vaccines and anti-viral therapies. The Editorial policy of Virology Journal is to publish all research which is assessed by peer reviewers to be a coherent and sound addition to the scientific literature, and puts less emphasis on interest levels or perceived impact.